Quantcast

Latest Diabetic retinopathy Stories

2011-04-08 01:30:00

TARRYTOWN, N.Y. and BERLIN, April 8, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Bayer HealthCare today announced that they have initiated the first of two Phase 3 clinical trials evaluating the efficacy and safety of VEGF Trap-Eye (aflibercept ophthalmic solution), an investigational new agent for the treatment of certain eye diseases, in the treatment of Diabetic Macular Edema (DME). The companies are extending their development program for VEGF Trap-Eye in...

2011-04-07 11:06:00

LOUISVILLE, Ky., April 7, 2011 /PRNewswire/ -- Women are more susceptible to developing eye conditions than men. According to Women's Eye Health, two-thirds of blind and visually-impaired people are women. During the month of April, Dr. Mark Lynn & Associates is especially encouraging women to get an eye examination to help preserve their vision. "Three of four people who are blind or visually-impaired have a condition that is preventable or curable," said Dr. Mark Lynn, an...

2011-04-07 10:54:00

NASHVILLE, Tenn., April 7, 2011 /PRNewswire/ -- Women are more susceptible to developing eye conditions than men. According to Women's Eye Health, two-thirds of blind and visually-impaired people are women. During the month of April, Dr. Mark Lynn & Associates is especially encouraging women to get an eye examination to help preserve their vision. "Three of four people who are blind or visually-impaired have a condition that is preventable or curable," said Dr. Mark Lynn, an...

2011-03-24 15:30:00

SOUTH PORTLAND, Maine, March 24, 2011 /PRNewswire/ -- Anthem Blue Cross and Blue Shield in Maine is now offering Blue View Vision(SM), an affordable and flexible vision plan that provides access to more than 125 network providers across the state, and more than 50,000 providers and provider locations nationwide. The Blue View Vision(SM) network includes ophthalmologists, optometrists, and opticians. In addition to private practitioners, Blue View Vision(SM)'s broad national network...

2011-03-22 14:18:00

LOUISVILLE, Ky. March 22, 2011 /PRNewswire/ -- Diabetes is often called the "silent killer" because people who have it are often unaware they are affected. According to the American Diabetes Association, diabetes affects 26 million people - including children - in the United States. Approximately one-quarter of those people do not know they're living with the disease. "Many people are at risk of developing type 2 diabetes, which can have serious effects on a person's eyesight," said Dr....

2011-03-22 14:07:00

NASHVILLE, March 22, 2011 /PRNewswire/ -- Diabetes is often called the "silent killer" because people who have it are often unaware they are affected. According to the American Diabetes Association, diabetes affects 26 million people - including children - in the United States. Approximately one-quarter of those people do not know they're living with the disease. "Many people are at risk of developing type 2 diabetes, which can have serious effects on a person's eyesight," said Dr. Mark...

2011-03-21 03:09:00

LONDON, March 21, 2011 /PRNewswire-FirstCall/ -- Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company") a leading global RNA interference (RNAi) therapeutics company, announces today that its partner, Quark Pharmaceuticals, has received results from a prospective randomized Phase 2 trial, the DEGAS study. The study evaluated the safety and efficacy of PF-04523655 (RTP801I- 14) in patients with diabetic macular edema (DME). PF-04523655 incorporates Silence's AtuRNAi technology...

2011-03-18 17:12:00

FREMONT, Calif., March 18, 2011 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a pharmaceutical company engaged in the discovery and development of RNAi-based therapeutics, today announced that it has received results from a prospective randomized Phase 2 trial, the DEGAS study. This study evaluated the safety and efficacy of PF-04523655 (RTP801I-14) in patients with diabetic macular edema (DME). 184 patients were randomly assigned to four treatment groups; three dose levels of PF-04523655...

2011-03-11 08:33:00

NORTH HAVEN, Conn., March 11, 2011 /PRNewswire/ -- Anthem Blue Cross and Blue Shield in Connecticut is now offering Blue View Vision, an affordable and flexible vision plan that provides access to more than 700 network providers in Connecticut, and more than 50,000 providers and provider locations nationwide. The Blue View Vision network includes ophthalmologists, optometrists, and opticians. In addition to private practitioners, Blue View Vision provides network access to retailers with...

2011-02-22 07:00:00

TARRYTOWN, N.Y., Feb. 22, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that the company submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for VEGF Trap-Eye for the treatment of the neovascular form of age-related macular degeneration (wet AMD). Under the Prescription Drug User Fee Act (PDUFA), the goal for a standard review time from submission to FDA action is ten months. Regeneron's submission includes a...


Word of the Day
reremouse
  • A bat.
The word 'reremouse' comes from Middle English reremous, from Old English hrēremūs, hrērmūs ("bat"), equivalent to rear (“to move, shake, stir”) +‎ mouse.
Related